Listed by the USPTO as RZECZYCKI, PHILLIP MATTHEW
Tech Center 1600 • Art Units: 1621 1624 1625
This examiner grants 65% of resolved cases
RZECZYCKI, PHILLIP MATTHEW works in tech center 1600 and art unit 1621. The record includes 128 resolved cases, a 64.8% allowance rate, and a 37.0% interview lift. The median time to allowance is 1251 days, so applicants should plan for a prosecution process that may require sustained attention.
Innovstone Therapeutics Limited, Dana-Farber Cancer Institute Inc., and AbbVie Inc. are the leading companies associated with these cases. BIRCH STEWART KOLASCH & BIRCH, LLP, CARTER, DELUCA & FARRELL LLP, and Arnold & Porter Kaye Scholer LLP are the leading firms. The interview figure supports considering examiner discussions when refining arguments or claim scope.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | Non-Final OA | AbbVie Inc. |
| 17759817 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | Final Rejection | Board of Regents, The University of Texas System |
| 18277748 | UNSYMMETRIC LINEAR CARBONATE AND METHOD FOR PREPARING THEREOF | Final Rejection | LG CHEM, LTD. |
| 17999408 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | Non-Final OA | Baylor College of Medicine |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy64.8% of resolved applications examined by Phillip Matthew Rzeczycki were allowed (128 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +37.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Phillip Matthew Rzeczycki took 1,251 days on average from filing to allowance.
Phillip Matthew Rzeczycki examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
